Loading…
← CockpitCompetitor Analysis › GMED Globus Medical Inc Class AOpen in the cockpit ↗

Globus Medical Inc Class AGMEDCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of spine surgery implants and instruments plus surgical robotics/navigation for orthopedic and neurosurgery.

Momentum weak 30
Mkt cap
$9.34B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$154M
20-day average traded
Fwd P/E
13.7×
forward earnings
ROIC−WACC
+3.1 pp
WACC 9.9%
Hurdle
-25 pp
Req g minus delivered
Next earnings
97 days
23 Feb 2027
Close · USD$70.53
1D+0.8%
1W-6.5%
1M-10.7%
3M-17.7%
6M-16.1%
YTD-19.2%
1Y-15.7%
ATR %4.5%
Beta0.96
52w lowhigh30.4% off high

What Globus Medical does

Maker of spine surgery implants and instruments plus surgical robotics/navigation for orthopedic and neurosurgery.

Spine implants sell on consignment: Globus keeps sets in hospitals and is paid when a surgeon uses a piece, with independent distributors and its own reps earning commissions, so each surgeon's preference drives sales. Excelsius robots are sold or leased to hospitals to pull through implants. The 2023 merger with NuVasive combined two large spine-implant sellers.

Products and services

  • Spine implants
  • Excelsius surgical robotics/navigation
  • Trauma/enabling technologies

Customers

  • Spine/orthopedic surgeons
  • Neurosurgeons
  • Hospitals

Where it sits in the supply chain

  • Healthcare
  • Medical devices
  • Spine implants and surgical…

What could go right

  • Robotic-assisted spine surgery adoption
  • NuVasive merger synergies/cross-sell

What could go wrong

  • Spine implant pricing pressure
  • Integration risk from the 2023 NuVasive merger

Moat: narrow (installed base, switching costs, IP / patents). Growing surgical-robotics installed base and a broad spine-implant portfolio following the NuVasive merger.

Headquarters: Audubon, Pennsylvania, USA · Founded: 2003 · Employees: 6,000

Named competitors

Globus Medical at a glance

Size Globus Medical (GMED) is a United States Health Care company (Medical Specialties) with a market value of $9.34B, the 809th largest of 3,085 United States companies the cockpit tracks. Shares closed at $70.53 on 18 Nov 2026.

Performance Over six months the shares fell 16.1%, against +26.6% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 13.3% over the last twelve months (peer median +4.6%); the operating margin is 23.0% (peer median 16.6%).

Valuation It trades at 13.7× forward earnings against a peer median of 20.6× (2nd cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +30%, so the hurdle is -25 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.1 points above its cost of capital (9.9% WACC).

Short interest Short interest is 8.5% of the free float (30 Oct 2026).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 127GMED 83
Six months, rebased to 100: Globus Medical against the median of its 20 peers (local-currency closes).

Globus Medical financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$3.14B$2.94B$2.52B$1.57B$1.02B
Revenue growth—+17%+61%+53%—
Gross profit$2.06B$1.86B$1.36B$969M$741M
EBITDA$1.00B$818M$486M$347M$305M
Net income$558M$538M$103M$123M$190M
Free cash flow$767M$589M$405M$165M$104M
Capital expenditure$159M$174M$115M$78.3M$74.0M
Total debt$108M$119M$538M$521M$0

Quarterly statements and history in the cockpit →

Globus Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%+20%BRKRPODDBIOQGENDEMANTAVTR77016869COOALGN300832GETI-BBIMBLCO7747SNPEN7733YPSNCTECGMED6-month return →1-month return →
Up and to the right = strong over both horizons. Globus Medical is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×30×BRKRPODDBIOQGENDEMANTAVTR77016869COOALGN300832GETI-BBIMBLCO7747PEN7733YPSNCTECGMEDRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Globus Medical is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%0%20%BRKRPODDBIOQGENDEMANTAVTR77016869ALGN300832GETI-B7747SNPEN7733CTECGMEDGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Globus Medical is the large dot.

Globus Medical competitors and peer comparison

Head to head with its named competitors (GMED vs MDT vs SYK vs ZBH)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Globus Medical GMED$9.34B-16%+13%23%13.7×4.6%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Zimmer Biomet ZBH$19.6B+21%+7%16%11.7×7.4%

How Globus Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Globus Medical against its 20 peers (data as of 18 Nov 2026)
MeasureGMEDPeer medianRank in peer set
1-month return-10.7%+6.1%lowest of 21
6-month return-16.1%+26.6%lowest of 21
Distance from 52-week high-30.4%-9.5%3rd lowest of 21
Revenue growth (TTM)+13.3%+4.6%4th highest of 21
Operating margin23.0%16.6%5th highest of 21
Forward P/E13.7×20.6×2nd cheapest of 21
Growth the price implies (Req g, 7 yrs)4.6%10.6%4th least demanding of 20
Growth delivered (Del g)+30.1%+9.8%highest of 20
Hurdle (Req g minus delivered)-25.5 pp+2.0 ppleast demanding of 20
ROIC minus cost of capital+3.1 pp+2.5 pp10th highest of 21
EV / EBITDA8.9×13.6×2nd cheapest of 20
Net debt / EBITDA-0.4×1.0×5th least indebted of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
Bio-Rad Laboratories BIOUnited States$10.1B+29%+1%9%34.6×26.0%+0.3%
Qiagen QGENUnited States$10.2B+41%+2%25%19.5×8.6%+2.2%
Demant A/S DEMANT.CODenmark$10.4B+39%+10%18%23.2×5.8%+9.8%
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%
Cooper Companies (The) COOUnited States$11.6B-2%+5%19%13.4×9.4%+11.0%
Align Technology ALGNUnited States$11.6B0%+4%19%13.8×13.1%+10.3%
Shenzhen New Industries Biomedical Engineering 300832.SZChina$7.50B+21%+7%43%26.9×2.9%+15.7%
Getinge GETI-B.STSweden$7.45B+40%-4%14%21.1×5.0%+3.2%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%
Bausch + Lomb BLCO.TOCanada$7.41B+35%+11%9%18.3×12.0%+10.0%
Asahi Intecc 7747.TJapan$7.09B+24%+23%32%29.7×15.1%+18.8%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Ypsomed YPSN.SWSwitzerland$6.83B+27%-13%30%31.7×n/an/a
ConvaTec CTEC.LUnited Kingdom$6.78B+37%+2%16%17.7×17.2%+4.6%

Questions

Who are Globus Medical's main competitors?
Named competitors: Medtronic (Spine) (MDT), Stryker (Spine) (SYK), Zimmer Biomet (Spine) (ZBH). The cockpit's measured peer set (industry) also includes Bruker (BRKR), Insulet (PODD), Bio-Rad Laboratories (BIO), Qiagen (QGEN), Demant A/S (DEMANT.CO), Avantor (AVTR).
Is Globus Medical expensive compared with its peers?
On forward p/e it trades at 13.7× against a peer median of 20.6×, 2nd cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +30%, so the hurdle is -25 pp: the price already allows for a slowdown.
How has Globus Medical stock performed?
Over six months to 18 Nov 2026 the shares returned -16.1% against +26.6% for the median peer; over one year -15.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.